Cellectis (ALCLS) - Total Liabilities
Based on the latest financial reports, Cellectis (ALCLS) has total liabilities worth €248.85 Million EUR (≈ $290.93 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cellectis - Total Liabilities Trend (2002–2025)
This chart illustrates how Cellectis's total liabilities have evolved over time, based on quarterly financial data. See Cellectis current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Cellectis Competitors by Total Liabilities
The table below lists competitors of Cellectis ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adagene Inc
NASDAQ:ADAG
|
USA | $42.91 Million |
|
Peña Verde S.A.B
MX:PV
|
Mexico | MX$41.32 Billion |
|
Runway Growth Finance Corp
NASDAQ:RWAY
|
USA | $466.70 Million |
|
Vecima Networks Inc.
TO:VCM
|
Canada | CA$129.74 Million |
|
Caxton
JSE:CAT
|
South Africa | ZAC1.84 Billion |
|
Mandala Multifinance Tbk
JK:MFIN
|
Indonesia | Rp3.13 Trillion |
|
Z.M.H Hammerman Ltd
TA:ZMH
|
Israel | ILA1.25 Billion |
|
Journey Energy Inc
TO:JOY
|
Canada | CA$237.97 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Cellectis's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cellectis market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.11 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cellectis's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cellectis (2002–2025)
The table below shows the annual total liabilities of Cellectis from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €248.85 Million ≈ $290.93 Million |
-1.45% |
| 2024-12-31 | €252.51 Million ≈ $295.21 Million |
+1.18% |
| 2023-12-31 | €249.57 Million ≈ $291.78 Million |
+84.49% |
| 2022-12-31 | €135.28 Million ≈ $158.15 Million |
-7.09% |
| 2021-12-31 | €145.60 Million ≈ $170.22 Million |
-9.35% |
| 2020-12-31 | €160.62 Million ≈ $187.79 Million |
+43.42% |
| 2019-12-31 | €112.00 Million ≈ $130.94 Million |
+121.48% |
| 2018-12-31 | €50.57 Million ≈ $59.12 Million |
+7.64% |
| 2017-12-31 | €46.98 Million ≈ $54.92 Million |
-17.05% |
| 2016-12-31 | €56.63 Million ≈ $66.21 Million |
-33.11% |
| 2015-12-31 | €84.67 Million ≈ $98.99 Million |
-10.83% |
| 2014-12-31 | €94.95 Million ≈ $111.01 Million |
+153.46% |
| 2013-12-31 | €37.46 Million ≈ $43.80 Million |
+12.10% |
| 2012-12-31 | €33.42 Million ≈ $39.07 Million |
-64.77% |
| 2011-12-31 | €94.86 Million ≈ $110.91 Million |
+396.58% |
| 2010-12-31 | €19.10 Million ≈ $22.33 Million |
+5.44% |
| 2009-12-31 | €18.12 Million ≈ $21.18 Million |
+23.92% |
| 2008-12-31 | €14.62 Million ≈ $17.09 Million |
+41.54% |
| 2007-12-31 | €10.33 Million ≈ $12.08 Million |
+99.77% |
| 2006-12-31 | €5.17 Million ≈ $6.05 Million |
+21.87% |
| 2005-12-31 | €4.24 Million ≈ $4.96 Million |
+144.84% |
| 2004-12-31 | €1.73 Million ≈ $2.03 Million |
+37.76% |
| 2003-12-31 | €1.26 Million ≈ $1.47 Million |
-3.16% |
| 2002-12-31 | €1.30 Million ≈ $1.52 Million |
-- |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more